drugset / Trial / NCT04216355
Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT
NaSingle-groupOpen-labelTreatment
Summary
This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .
Timeline
- Start
- 2020-01
- Primary completion
- 2021-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aclarubicin | Small molecule | 5 mg/m2 | Intravenous |
| Subject | Azacitidine | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 10 mg/m2 | Intravenous |